Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma

(2021) E. A. Rozeman et al.   NATURE MEDICINE

Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)

(2021) Alexander M. Menzies et al.   NATURE MEDICINE

Determinants of Resistance to Checkpoint Inhibitors

(2020) Linda Tran et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Systemic Therapy for Melanoma: ASCO Guideline

(2020) Rahul Seth et al.   JOURNAL OF CLINICAL ONCOLOGY

The IMPemBra trial, a phase II study comparing pembrolizumab with intermittent/short‐term dual MAPK pathway inhibition plus pembrolizumab in melanoma patients harboring the BRAFV600 mutation.

(2020) Elisa A. Rozeman et al.   JOURNAL OF CLINICAL ONCOLOGY

The human tumor microbiome is composed of tumor type–specific intracellular bacteria

(2020) Deborah Nejman et al.   SCIENCE

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition

(2020) Jenny H. Lee et al.   Nature Communications

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

(2020) Harriet M. Kluger et al.   Journal for ImmunoTherapy of Cancer

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial

(2020) Ralf Gutzmer et al.   LANCET

Opportunities for Small Molecules in Cancer Immunotherapy

(2020) Sabina Y. van der Zanden et al.   TRENDS IN IMMUNOLOGY

Histone Deacetylase Inhibitors to Overcome Resistance to Targeted and Immuno Therapy in Metastatic Melanoma

(2020) Minjeong Yeon et al.   Frontiers in Cell and Developmental Biology

LBA45 First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)

(2020) P.A. Ascierto et al.   ANNALS OF ONCOLOGY

Getting under the skin: The role of CDK4/6 in melanomas

(2020) Linghong Guo et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models

(2020) Satish Noonepalle et al.   JOURNAL OF MEDICINAL CHEMISTRY

Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

(2020) Paolo A Ascierto et al.   LANCET ONCOLOGY

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

(2020) Reinhard Dummer et al.   NATURE MEDICINE

Transcriptional regulators and alterations that drive melanoma initiation and progression

(2020) Romi Gupta et al.   ONCOGENE

Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer

(2020) Shang-Jui Wang et al.   Journal for ImmunoTherapy of Cancer

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

(2020) H. Gogas et al.   ANNALS OF ONCOLOGY

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

(2020) Amita Patnaik et al.   CLINICAL CANCER RESEARCH

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

(2020) Antoni Ribas et al.   Nature Communications

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

(2020) Pier Francesco Ferrucci et al.   Journal for ImmunoTherapy of Cancer

Genomic correlates of response to immune checkpoint blockade

(2019) Tanya E. Keenan et al.   NATURE MEDICINE

Modulating the microbiome to improve therapeutic response in cancer

(2019) Jennifer L McQuade et al.   LANCET ONCOLOGY

Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)

(2019) Yifan Feng et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors

(2019) M D Hellmann et al.   ANNALS OF ONCOLOGY

Cutaneous Melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

(2019) Daniel G. Coit et al.   Journal of the National Comprehensive Cancer Network

The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma

(2019) Hao Chen et al.   OncoImmunology

Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies

(2019) Stephen A. Luebker et al.   Frontiers in Oncology

The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?

(2019) A Elkrief et al.   ANNALS OF ONCOLOGY

Efficacy of PD-1–based immunotherapy after radiologic progression on targeted therapy in stage IV melanoma

(2019) Sophia Kreft et al.   EUROPEAN JOURNAL OF CANCER

Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

(2019) Ryan J. Sullivan et al.   NATURE MEDICINE

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

(2019) Paolo Antonio Ascierto et al.   NATURE MEDICINE

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

(2019) Antoni Ribas et al.   NATURE MEDICINE

Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer

(2019) Nadina Tinsley et al.   ONCOLOGIST

Role of angiogenesis in melanoma progression: Update on key angiogenic mechanisms and other associated components

(2019) Woo Cheal Cho et al.   SEMINARS IN CANCER BIOLOGY

On the Horizon: Targeting Next-Generation Immune Checkpoints for Cancer Treatment

(2019) Grazia R. Tundo et al.   CHEMOTHERAPY

Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial

(2019) Anna Maria Di Giacomo et al.   CLINICAL CANCER RESEARCH

Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial

(2019) Xinan Sheng et al.   JOURNAL OF CLINICAL ONCOLOGY

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

(2019) Georgina V Long et al.   LANCET ONCOLOGY

Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape

(2019) Arsen Osipov et al.   Journal for ImmunoTherapy of Cancer

1312PDSafety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): A single center phase II study

(2019) E M Burton et al.   ANNALS OF ONCOLOGY

LBA71Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study)

(2019) H Jespersen et al.   ANNALS OF ONCOLOGY

Immune checkpoint inhibitor-based combinations: is dose escalation mandatory for phase I trials?

(2019) V Simmet et al.   ANNALS OF ONCOLOGY

Targeted Therapy and Immunotherapy: Emerging Biomarkers in Metastatic Melanoma

(2019) Patricia M. LoRusso et al.   Pigment Cell & Melanoma Research

DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load

(2019) Hyunchul Jung et al.   Nature Communications

Combining epigenetic and immune therapy to overcome cancer resistance

(2019) Stephanie Gomez et al.   SEMINARS IN CANCER BIOLOGY

The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy

(2018) Vancheswaran Gopalakrishnan et al.   CANCER CELL

LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade

(2018) Wanqiang Sheng et al.   CELL

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

(2018) Jan P. Böttcher et al.   CELL

Immune Checkpoint Blockade across the Cancer Care Continuum

(2018) Beth A. Helmink et al.   IMMUNITY

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

(2018) James Larkin et al.   JOURNAL OF CLINICAL ONCOLOGY

Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy

(2018) Kui Li et al.   JOURNAL OF DRUG TARGETING

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

(2018) Rebekka Weber et al.   Frontiers in Immunology

Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways

(2018) Pottayil G. Sasikumar et al.   BIODRUGS

Phase 2 trial of the IDO pathway inhibitor indoximod plus checkpoint inhibition for the treatment of patients with advanced melanoma.

(2018) Yousef Zakharia et al.   JOURNAL OF CLINICAL ONCOLOGY

The COX2 Effector Microsomal PGE2 Synthase 1 is a Regulator of Immunosuppression in Cutaneous Melanoma

(2018) Sun-Hee Kim et al.   CLINICAL CANCER RESEARCH

HGF/c-MET Signaling in Melanocytes and Melanoma

(2018) Malgorzata Czyz   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial

(2018) Frank Stephen Hodi et al.   LANCET ONCOLOGY

Enhancing the Anticancer Efficacy of Immunotherapy through Combination with Histone Modification Inhibitors

(2018) Wanyu Sun et al.   Genes

Whole-genome landscapes of major melanoma subtypes

(2017) Nicholas K. Hayward et al.   NATURE

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma

(2017) Jeffrey Weber et al.   NEW ENGLAND JOURNAL OF MEDICINE

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

(2017) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

(2017) Diego Chowell et al.   SCIENCE

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies

(2017) Matthew J. Reilley et al.   Journal for ImmunoTherapy of Cancer

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

Angiogenesis in melanoma: an update with a focus on current targeted therapies

(2016) George Jour et al.   JOURNAL OF CLINICAL PATHOLOGY

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

(2016) N. McGranahan et al.   SCIENCE

Targeted Therapy and Checkpoint Immunotherapy Combinations for the Treatment of Cancer

(2016) Paul E. Hughes et al.   TRENDS IN IMMUNOLOGY

Epigenetic Determinants of Cancer

(2016) Stephen B. Baylin et al.   Cold Spring Harbor Perspectives in Biology

Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma

(2016) Asim Amin et al.   Journal for ImmunoTherapy of Cancer

Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity

(2015) Santiago Zelenay et al.   CELL

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab

(2015) David R. Minor et al.   Pigment Cell & Melanoma Research

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

(2015) E. M. Van Allen et al.   SCIENCE

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab

(2014) Ahmad A. Tarhini et al.   PLoS One

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2014) F. S. Hodi et al.   Cancer Immunology Research

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

(2014) Mizuki Nishino et al.   Journal for ImmunoTherapy of Cancer

Adoptive T-cell Transfer Therapy and Oncogene-Targeted Therapy for Melanoma: The Search for Synergy

(2013) M. L. M. Kwong et al.   CLINICAL CANCER RESEARCH

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

(2013) Kerstin Trunzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

(2013) Antoni Ribas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY